Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10447781 | 0.89 | NOTUM (0.78) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL6877497 | 0.83 | NOTUM (0.60) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL1186707 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL21777006 | 0.78 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL482167 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL8117312 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL239581 | 0.78 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL11102521 | 0.78 | NOTUM (1.00) | NOTUMCYP19A1KEAP1 | |
| SCHEMBL76794 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1BRS3 | |
| SCHEMBL3681868 | 0.78 | NOTUM (0.64) | NOTUMCYP19A1KEAP1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| CN-101743229-A | quinazolinamide derivatives | MERCK PATENT GMBH | 2010-06-16 | — | — | CN | claimed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
| CN-101743229-B | Quinazolinamide derivatives | MERCK PATENT GMBH | 2013-08-14 | — | — | CN | disclosed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| CN-101743229-A | quinazolinamide derivatives | MERCK PATENT GMBH | 2010-06-16 | — | — | CN | disclosed |
| EP-2164833-A2 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009010139-A2 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | WO | disclosed |
| EP-0796270-A2 | PEPTIDE COMPOUNDS FOR PREVENTION AND/OR TREATMENT OF NO-MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | NOTUM 4474/4885CYP19A1 1951/4885KEAP1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.